NO20064676L - Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre - Google Patents

Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre

Info

Publication number
NO20064676L
NO20064676L NO20064676A NO20064676A NO20064676L NO 20064676 L NO20064676 L NO 20064676L NO 20064676 A NO20064676 A NO 20064676A NO 20064676 A NO20064676 A NO 20064676A NO 20064676 L NO20064676 L NO 20064676L
Authority
NO
Norway
Prior art keywords
dimethylsuccinyl
betulinic acid
dsb
pharmaceutical salts
salts
Prior art date
Application number
NO20064676A
Other languages
English (en)
Inventor
Martin Dale Power
David Eugene Martin
Original Assignee
Panacos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacos Pharmaceuticals Inc filed Critical Panacos Pharmaceuticals Inc
Publication of NO20064676L publication Critical patent/NO20064676L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives salter av 3-O-(3',3'-dimetylsuccinyl) betulinsyre (DSB). Spesielt beskrives fremstilling, farmasøytisk evaluering og in vivo biotilgjengelighetsevaluering av N-metyl-D-glucamin og alkaliesaltformer av DSB. Videre beskrives farmasøytiske preparater inkludert disse saltformer for anvendelse i metoder for behandling av HIV og relaterte sykdommer. Det tilveiebringes også metoder for å fremstille saltene av DSB og også de farmasøytiske preparater.
NO20064676A 2004-03-17 2006-10-16 Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre NO20064676L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55355404P 2004-03-17 2004-03-17
US58467404P 2004-07-02 2004-07-02
PCT/US2005/008935 WO2005090380A1 (en) 2004-03-17 2005-03-17 Pharmaceuticals salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid

Publications (1)

Publication Number Publication Date
NO20064676L true NO20064676L (no) 2006-12-01

Family

ID=34993638

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064676A NO20064676L (no) 2004-03-17 2006-10-16 Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre

Country Status (11)

Country Link
US (2) US20050239748A1 (no)
EP (1) EP1730163A4 (no)
JP (1) JP2007529544A (no)
AU (1) AU2005224260A1 (no)
BR (1) BRPI0508854A (no)
CA (1) CA2560266A1 (no)
IL (1) IL178128A0 (no)
MX (1) MXPA06010592A (no)
NO (1) NO20064676L (no)
RU (1) RU2387665C2 (no)
WO (1) WO2005090380A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235486A1 (en) * 2005-04-12 2006-10-19 Panacos Pharmaceuticals, Inc. Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-N-methyl-D-glucamine
BRPI0619936A2 (pt) * 2005-12-16 2011-10-25 Panacos Pharmaceuticals Inc preparação de sais farmacêuticos de ácido 3-o-(3',3'- dimetilsuccinil) betulìnico
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
CZ300722B6 (cs) * 2006-09-27 2009-07-22 Univerzita Karlova v Praze, Prírodovedecká fakulta Zpusob prípravy inkluzního komplexu pentacyklických a tetracyklických terpenoidu a farmaceutického prostredku obsahujícího tento inkluzní komplex, inkluzní komplex pentacyklického nebo tetracyklického terpenoidu a farmaceutický prostredek obsahující
TW200837074A (en) 2006-11-03 2008-09-16 Panacos Pharmaceuticals Inc Extended triterpene derivatives
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
JP2009120516A (ja) * 2007-11-13 2009-06-04 Tokyo Medical Univ 抗ウィルス剤
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
US8802727B2 (en) * 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
SI2576586T1 (sl) 2010-06-04 2015-11-30 Bristol-Myers Squibb Company C-28 amidi derivatov modificirane c-3 betulinske kisline kot inhibitorji zorenja hiv
JP5752789B2 (ja) * 2010-06-04 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体
US20140221328A1 (en) * 2011-01-10 2014-08-07 Bandi Parthasaradhi Reddy Pharmaceutically acceptable salts of novel betulinic acid derivatives
HUE026371T2 (en) 2011-01-31 2016-05-30 Bristol Myers Squibb Co C-28 amines from modified C-3 betulinic acid derivatives as anti-HIV matrices
PE20141152A1 (es) 2011-01-31 2014-09-22 Bristol Myers Squibb Co Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana
RU2489147C2 (ru) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Фармацевтическая антибактериальная композиция для местного применения на основе активных биометаллокомплексов
WO2013043778A1 (en) 2011-09-21 2013-03-28 Bristol-Myers Squibb Company Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
MX2015010003A (es) 2013-02-06 2015-10-30 Squibb Bristol Myers Co Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
EP2958930A1 (en) 2013-02-25 2015-12-30 Bristol-Myers Squibb Company C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
EA030178B1 (ru) 2014-04-11 2018-06-29 Вайв Хелткер Юкей (№ 4) Лимитед Тритерпеноиды с активностью ингибиторов созревания вич, замещенные в положении 3 неароматическим кольцом, имеющим галогеналкильный заместитель
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
AU2015346311A1 (en) 2014-11-14 2017-06-08 Viiv Healthcare UK (No5) Limited C17-aryl substituted betulinic acid analogs
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN107638571B (zh) 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞口服药物组合物及其制备方法
CN107625967B (zh) 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
CN111417384A (zh) 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经***病况的方法和改进的神经保护性组合物
EP3681508A4 (en) 2017-09-14 2021-05-19 Phoenix Biotechnology, Inc. METHOD AND COMPOSITION FOR THE TREATMENT OF VIRAL INFECTION
EP3796900A4 (en) 2018-06-29 2022-03-30 DFH Therapeutics TRITERPENE AMINE DERIVATIVES
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
KR20220151038A (ko) 2020-03-31 2022-11-11 피닉스 바이오테크놀러지 인코포레이티드. 코로나바이러스 감염 예방를 위한 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839344A (en) * 1973-03-28 1974-10-01 Schering Corp N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid
US4205073A (en) * 1975-04-30 1980-05-27 Schering Corporation Anti-diarrheal anilino nicotinic acids and method of using same
US4377583A (en) * 1981-08-21 1983-03-22 Mead Johnson & Company N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid
JPS60163897A (ja) * 1984-02-06 1985-08-26 Tokyo Tanabe Co Ltd ウルソデオキシコ−ル酸メグルミン塩およびその注射剤
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JP2614407B2 (ja) * 1991-10-16 1997-05-28 シェリング・コーポレーション 親油性オリゴ糖抗生物質塩組成物
FR2683531B1 (fr) * 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
GB9613455D0 (en) * 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US6043245A (en) * 1997-09-25 2000-03-28 Schering Corporation Tetrahydrofuran antifungal phosphate
US6670345B1 (en) * 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
NZ506623A (en) * 1998-03-02 2002-10-25 Univ North Carolina Acylated betulin and dihydrobetulin derivatives, preparation thereof and use in treatment of retroviral infections
WO1999067284A2 (en) * 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6147077A (en) * 1999-04-29 2000-11-14 Sepracor Inc. 2R,4S-hydroxyitraconazole isomers
EP1282606B1 (en) * 2000-05-08 2015-04-22 Janssen Pharmaceutica NV Hiv replication inhibiting pyrimidines and triazines
US7365221B2 (en) * 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
AU2004210162A1 (en) * 2003-01-29 2004-08-19 Panacos Pharmaceuticals, Inc. Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
KR20060096147A (ko) * 2003-09-26 2006-09-07 파나코스 파마슈티칼즈, 인크. 신규한 트리터펜 유도체, 그 제조방법 및 용도

Also Published As

Publication number Publication date
WO2005090380A1 (en) 2005-09-29
BRPI0508854A (pt) 2007-08-28
EP1730163A4 (en) 2009-12-30
MXPA06010592A (es) 2007-06-12
US20120214775A1 (en) 2012-08-23
EP1730163A1 (en) 2006-12-13
AU2005224260A1 (en) 2005-09-29
RU2387665C2 (ru) 2010-04-27
JP2007529544A (ja) 2007-10-25
CA2560266A1 (en) 2005-09-29
RU2006136409A (ru) 2008-04-27
IL178128A0 (en) 2006-12-31
US20050239748A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
TNSN07290A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
NO20021701L (no) Fremgangsmåte for fremstilling av et konjugat av polyglutamat og et terapeutisk middel
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
NZ709704A (en) Protein formulations and methods of making same
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
PT1687305E (pt) Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
TW200745155A (en) Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl)betulinic acid
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
WO2002070014A8 (en) Compositions comprising an o/w emulsion containing conjugated linoleic acid
TW200800977A (en) A new salt
WO2008074960A3 (fr) Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
AU2001249267A1 (en) Methods and compositions for elucidating protein expression profiles in cells
Dezzutti et al. Pharmacodynamic Activity in Ectocervical and Colonic Tissue of Dapivirine, Maraviroc, and Combination Topical Gels for HIV Prevention

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application